default author photo

Miklos Egyed

Kaposi MorCounty Teaching Hospital

Hungary

SCHOLARLY PAPERS

2

DOWNLOADS

347

TOTAL CITATIONS

6

Scholarly Papers (2)

1.

Ropeginterferon Alfa-2b versus Standard Therapy for Polycythaemia Vera; a Randomised, Controlled, Phase III Trial

Number of pages: 226 Posted: 27 Jul 2019
Medical University of Vienna - Division of Haematology and Blood Coagulation, AOP Orphan Pharmaceuticals AG, Medical University of Plovdiv, University Hospital in Krakow, Multiprofile Hospital for Active Treatment "Sveta Marina", Kaposi MorCounty Teaching Hospital, Samara Kalinin Regional Clinical Hospital, University Hospital Hradec Kralove, University of Debrecen - Faculty of Medicine, Cherkasy Regional Oncology Centre, Multiprofile Hospital for Active Treatment - HristoBotev, University Hospital Brno, Yaroslavl Regional Clinical Hospital, AOP Orphan Pharmaceuticals AG, AOP Orphan Pharmaceuticals AG, University of Copenhagen, Medical University of Vienna, University of Paris and Independent
Downloads 237 (323,233)
Citation 6

Abstract:

Loading...

Ropeginterferon alfa 2b, Hydroxyurea, Treatment of Polycythemia vera, randomized phase III trial

2.

Selinexor in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (SADAL): A Single-Arm Multinational Phase 2 Trial

Number of pages: 196 Posted: 11 Feb 2020
University of Liverpool, Université Libre de Bruxelles (ULB) - Institute Jules Bordet, University of Turin, NHS Foundation Trust - Addenbrooke's Hospital, Hackensack University - Hackensack University Medical Center, Leiden University - Leiden University Medical Center (LUMC), Centre Hospitalier Universitaire (CHU) de Bordeaux - Clinical Hematology Service, St. Vincent's Hospital Sydney, VU University Amsterdam - Department of Hematology, Dr. B. R. A. Institute Rotary Cancer Hospital AIIMS, Aix-Marseille University - Institut Paoli-Calmettes, Sorbonne University - University Hospitals Pitié Salpêtrière - Charles Foix, Tel Aviv University - Rabin Medical Center, Cleveland Clinic - Department of Hematology & Medical Oncology, Medical University of Vienna, Hospital Germans Trias y Pujol (ICO-IJC) - Hematology Department, State University of New York (SUNY), Stony Brook, University of Paris, Virgen del Rocio University, Kaposi MorCounty Teaching Hospital, Institute of Medical Sciences & SUM Hospital, Ghent University - Ghent University Hospital, National and Kapodistrian University of Athens, Instytut Hematologii i Transfuzjologii, Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Catholic University of Louvain (UCL) - Cliniques Universitaires Saint-Luc and Hospital Universitario La Paz
Downloads 110 (640,165)

Abstract:

Loading...

Selinexor, SADAL trial, Relapsed/Refractory, Diffuse Large B-cell Lymphoma